Literature DB >> 6243853

Causes of death and metastatic patterns in patients with mammary cancer. Ten-year autopsy study.

S Y Cho, H Y Choi.   

Abstract

As periodic evaluation of the causes of death in cancer patients may provide guidelines for further research on supportive care in cancer, the authors studied autopsy records of 144 mammary-cancer patients from the past ten years. The causes of death were analyzed and compared for the first and second five-year periods. During the first five-year period (65 cases), death was caused by the malignant process itself in 70.8% of the patients, by infection in 10.8% and by hemorrhage in 7.7%. During the second five-year period (79 cases), the malignant process itself was still the most frequent cause of death but in only 47.4% of the patients, and deaths due to infections (23.7%) and hemorrhages (9.2%) were relatively more frequent, without noticeable changes in the patients' survival times. These findings may be related to the more aggressive methods of treatment applied in recent years. The metastases to the organs tended to be massive, and except for the lymph nodes, the lung was the organ most frequently involved by tumors (60%), followed by bone (54%), liver (54%), adrenal gland (36%), pleura (36%) and brain (26%). As the chance of life-threatening infections is great in mammary cancer, the early detection and treatment of infections in mammary-cancer patients could become an important factor in prolonging the survival of these patients.

Entities:  

Mesh:

Year:  1980        PMID: 6243853     DOI: 10.1093/ajcp/73.2.232

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  22 in total

1.  Durable clinical benefit with exemestane in leptomeningeal metastasis of breast cancer.

Authors:  Luis Miguel Navarro Martín; Alberto Ocaña Fernández; Cesar Augusto Rodríguez Sánchez; Isabel Ruiz Martín; Juan Jesús Cruz Hernández
Journal:  Clin Transl Oncol       Date:  2005-09       Impact factor: 3.405

2.  Triple-negative breast cancer with brain metastasis in a pregnant woman.

Authors:  Francisco Trinca; Mariana Inácio; Teresa Timóteo; Rui Dinis
Journal:  BMJ Case Rep       Date:  2017-02-20

3.  Breast cancer at bone metastatic sites: recent discoveries and treatment targets.

Authors:  Osama Hussein; Svetlana V Komarova
Journal:  J Cell Commun Signal       Date:  2011-01-19       Impact factor: 5.782

Review 4.  Assessing the autopsy.

Authors:  P N Nemetz; J Ludwig; L T Kurland
Journal:  Am J Pathol       Date:  1987-08       Impact factor: 4.307

5.  Gemifloxacin inhibits migration and invasion and induces mesenchymal-epithelial transition in human breast adenocarcinoma cells.

Authors:  Tun-Chieh Chen; Ya-Ling Hsu; Yu-Chieh Tsai; Yu-Wei Chang; Po-Lin Kuo; Yen-Hsu Chen
Journal:  J Mol Med (Berl)       Date:  2013-09-05       Impact factor: 4.599

6.  Clinicopathological Factors Related to the Prognosis of Metastatic Breast Cancer Patients after Development of Brain Metastasis.

Authors:  Jun Yamamura; Norikazu Masuda; Hiroyuki Yasojima; Makiko Mizutani; Keiko Kuriyama; Shoji Nakamori; Mitsugu Sekimoto; Masayuki Mano; Eiichi Tanaka; Masahiro Nonaka
Journal:  Breast Care (Basel)       Date:  2015-12-02       Impact factor: 2.860

Review 7.  Patterns of metastasis and natural courses of breast carcinoma.

Authors:  Y T Lee
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

8.  Characterization of brain and bone-metastasizing clones selected from an ethylnitrosourea-induced rat mammary carcinoma.

Authors:  D G Hall; G Stoica
Journal:  Clin Exp Metastasis       Date:  1994-07       Impact factor: 5.150

9.  Radiotherapy of brain metastases from breast cancer: Treatment results and prognostic factors.

Authors:  Julia Kühnöl; Caspar Kühnöl; Dirk Vordermark
Journal:  Oncol Lett       Date:  2016-03-17       Impact factor: 2.967

10.  A murine model of bone marrow micrometastasis in breast cancer.

Authors:  Barbara O'Kane Murphy; Shantaram Joshi; Anne Kessinger; Elizabeth Reed; J Graham Sharp
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.